Table 3.
NIR light-triggered drug delivery systems for bone cancer photo-chemotherapy
| Nanocarriers structure | Photoresponsive agents | Radiation conditions | The mechanisms of phototherapeutic effects | Anticancer drugs | Encapsulation efficiency | Release efficiency | Application | References | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Wavelength (nm) | Power density (W·cm-2) | Radiation time (min) | ||||||||
| Bismuth sulfide (Bi2S3)@mesoporous silica nanoparticles (MSNs) | Bi2S3 | 808 | 1 | 10 | The outstanding photothermal conversion efficiency of Bi2S3 nanoparticles | DOX | 99.85% | Almost 30% | Osteosarcoma | Lu Y. et al. 46 |
| PDA coated bioactive glass nanoparticle (BGN) | PDA | 808 | 1.4 | 10 | The stable NIR light-excited photothermal effects of PDA coating | DOX | 59% | Almost 10% (50th day, pH = 5.5) | Bone cancer therapy and bone tissue regeneration | Xue Y. et al. 76 |
| Gold nanorods enclosed inside mesoporous silica nanoparticles | Gold nanorods | 808 | 1.2 | 10 | The outstanding photothermal conversion efficiency of gold nanorods | ZOL | 35.4%. | Almost 90% | Breast cancer bone metastasis | Sun W. et al. 77 |
| PDA-alendronate /SN38 nanoparticles | PDA | 808 | 3.6 | 30 | Highly efficient photothermal effects of PDA nanoparticles | SN38 | - | Over 50% | Malignant bone tumors and osteolysis | Wang Y. et al. 80 |
| PDA-decorated nano-hydroxyapatite chitosan hydrogel | PDA | 808 | 2 | 2 | The excellent photothermal effects of PDA coating | Cisplatin | 91.49% | Sustained release: 71% (9th day) | Breast cancer bone metastasis and bone tissue regeneration | Luo S. et al. 81 |
| Bovine serum albumin (BSA)-iridium oxide (IrO2) nanoparticles | IrO2 | 808 | 1 | 5 | The superior photothermal conversion efficiency of IrO2 nanoparticles | DOX | 27.4 wt% | 46% (pH = 7.4), 68% (pH = 5.0) | Osteosarcoma | Gu W. et al. 82 |
DOX: Doxorubicin, PDA: Polydopamine, ZOL: Zoledronic acid, SN38: 7-ethyl-10-hydroxycamptothecin.